CLINICAL TRIALS AND OBSERVATIONS Late cardiotoxicity after treatment for Hodgkin lymphoma

We assessed cardiovascular disease (CVD) incidence in 1474 survivors of Hodgkin lymphoma (HL) younger than 41 years at treatment (1965-1995). Multivari-able Cox regression and competing risk analyses were used to quantify treatment effects on CVD risk. After a median fol-low-up of 18.7 years, risks of myocardial infarction (MI) and congestive heart fail-ure (CHF) were strongly increased com-pared with the general population (stan-dardized incidence ratios [SIRs] 3.6 and 4.9, respectively), resulting in 35.7 excess cases of MI and 25.6 excess cases of CHF per 10 000 patients/year. SIRs of all CVD